REDWOOD CITY, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today highlighted data from several clinical studies that will be presented at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2014 in Chicago, IL. OncoMed will present new clinical data, as follows:
"Across our clinical pipeline, we are obtaining new data for OncoMed's anti-cancer stem cell therapeutics," said Jakob Dupont, M.D., OncoMed's Chief Medical Officer. "The results being presented at ASCO for several OncoMed candidates demonstrate acceptable safety and tolerability profiles with manageable or reversible side effects observed, both as single agents and in combination with standard chemotherapy. Fzd8-Fc, anti-Notch 2/3 and demcizumab are all showing early indications of biomarker and anti-tumor activity."
- Fzd8-Fc (OMP-54F28) Phase 1a trial in patients with advanced solid tumors (oral presentation);
- Anti-Notch 2/3 (OMP-59R5) Phase 1b/2 PINNACLE study in small cell lung cancer; and
- Demcizumab (anti-DLL4, OMP-21M18) Phase 1b study in non-small cell lung cancer.
Read more: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=848073
Comments are closed.